90 related articles for article (PubMed ID: 2507174)
1. [Changes in indicators of nonspecific humoral immunity in carriers of N. meningitidis].
Tomásik E
Cesk Epidemiol Mikrobiol Imunol; 1989 Sep; 38(5):280-5. PubMed ID: 2507174
[TBL] [Abstract][Full Text] [Related]
2. [Specific antibody response in carriers of N. meningitidis].
Tomásik E; Kuzemenská P
Cesk Epidemiol Mikrobiol Imunol; 1989 Jul; 38(4):221-7. PubMed ID: 2507173
[TBL] [Abstract][Full Text] [Related]
3. [Long-term monitoring of Neisseria meningitidis carrier state in the nasopharynx and seroprevalence of specific antibodies in immunized and non-immunized persons].
Kartusek S; Douda P; Gál P; Koudelková M; Marková Z; Krízová P; Musílek M
Epidemiol Mikrobiol Imunol; 1998 Dec; 47(4):145-9. PubMed ID: 9919815
[TBL] [Abstract][Full Text] [Related]
4. [Meningococcal meningitis: bacterial virulence, antibodies or complement?].
Pujadas Capmany R; Jané Pesquer J
Med Clin (Barc); 1984 Nov; 83(16):671-3. PubMed ID: 6439961
[No Abstract] [Full Text] [Related]
5. [Studies on serum meningococcal antibodies in patients with meningococcal meningitis and a healthy population].
Pang HM
Zhonghua Yu Fang Yi Xue Za Zhi; 1988 Jul; 22(4):233-5. PubMed ID: 3146488
[No Abstract] [Full Text] [Related]
6. The role of complement in anti-bacterial defence.
D'Amelio R; Biselli R
Ann Ital Med Int; 1994; 9(3):173-7. PubMed ID: 7946895
[TBL] [Abstract][Full Text] [Related]
7. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency.
Ross SC; Densen P
Medicine (Baltimore); 1984 Sep; 63(5):243-73. PubMed ID: 6433145
[TBL] [Abstract][Full Text] [Related]
8. Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease.
Litt DJ; Savino S; Beddek A; Comanducci M; Sandiford C; Stevens J; Levin M; Ison C; Pizza M; Rappuoli R; Kroll JS
J Infect Dis; 2004 Oct; 190(8):1488-97. PubMed ID: 15378443
[TBL] [Abstract][Full Text] [Related]
9. [Factors affecting the occurrence and development of invasive meningococcal disease and development of Neisseria meningitis carrier state--results of a nationwide prospective questionnaire survey of cases and controls].
Krízová P; Kríz B
Epidemiol Mikrobiol Imunol; 1999 Nov; 48(4):140-52. PubMed ID: 10658342
[TBL] [Abstract][Full Text] [Related]
10. Meningococcal vaccines in prevention and control of meningitis.
Saxena SN; Rawal IJ; Tripathi KK; Gupta P
Indian Pediatr; 1985 Jun; 22(6):453-65. PubMed ID: 3938978
[No Abstract] [Full Text] [Related]
11. Mucosal immunity and optimizing protection with meningococcal serogroup B vaccines.
Heyderman RS; Davenport V; Williams NA
Trends Microbiol; 2006 Mar; 14(3):120-4. PubMed ID: 16469496
[TBL] [Abstract][Full Text] [Related]
12. Factors influencing host susceptibility to meningococcal disease.
Winstanley FP; Blackwell CC; Weir DM
Biomed Pharmacother; 1985; 39(4):167-70. PubMed ID: 3933588
[TBL] [Abstract][Full Text] [Related]
13. An ELISA study of the antibody response after vaccination with a combined meningococcal group B polysaccharide and serotype 2 outer membrane protein vaccine.
Rosenqvist E; Tjade T; Frøholm LO; Frasch CE
NIPH Ann; 1983 Dec; 6(2):139-49. PubMed ID: 6427704
[TBL] [Abstract][Full Text] [Related]
14. Recurrent meningococcal meningitis associated with deficiencies of C8 and anti-meningococcal antibody.
Cooke RP; Zafar M; Haeney MR
J Clin Lab Immunol; 1987 May; 23(1):53-6. PubMed ID: 3112405
[TBL] [Abstract][Full Text] [Related]
15. Predictors of immunity after a major serogroup W-135 meningococcal disease epidemic, Burkina Faso, 2002.
Raghunathan PL; Jones JD; Tiendrebéogo SR; Sanou I; Sangaré L; Kouanda S; Dabal M; Lingani C; Elie CM; Johnson S; Ari M; Martinez J; Chatt J; Sidibe K; Schmink S; Mayer LW; Kondé MK; Djingarey MH; Popovic T; Plikaytis BD; Carlone GM; Rosenstein N; Soriano-Gabarró M
J Infect Dis; 2006 Mar; 193(5):607-16. PubMed ID: 16453255
[TBL] [Abstract][Full Text] [Related]
16. Intranasal immunization of mice with recombinant lipidated P2086 protein reduces nasal colonization of group B Neisseria meningitidis.
Zhu D; Barniak V; Zhang Y; Green B; Zlotnick G
Vaccine; 2006 Jun; 24(26):5420-5. PubMed ID: 16621173
[TBL] [Abstract][Full Text] [Related]
17. [Factors affecting Neisseria meningitidis and Neisseria lactamica carrier state].
Krízová P; Vlcková J
Epidemiol Mikrobiol Imunol; 1998 Dec; 47(4):131-6. PubMed ID: 9919812
[TBL] [Abstract][Full Text] [Related]
18. [Induction of anti-meningitis immunity using the synthetic peptides. I. The immunoreactive synthetic fragments of porin A from Neisseria meningitidis].
Koroev DO; Kotel'nikova OV; Vol'pina OM; Zhmak MN; Kupriianova MA; Agafonova SA; Alliluev AP; Litvinov IS; Nesmeianov VA; Ivanov VT
Bioorg Khim; 2000 May; 26(5):323-9. PubMed ID: 10900502
[TBL] [Abstract][Full Text] [Related]
19. Neisseria meningitidis serogroups A and W-135: carriage and immunity in Burkina Faso, 2003.
Mueller JE; Yaro S; Traore Y; Sangare L; Tarnagda Z; Njanpop-Lafourcade BM; Borrow R; Gessner BD
J Infect Dis; 2006 Mar; 193(6):812-20. PubMed ID: 16479516
[TBL] [Abstract][Full Text] [Related]
20. [Findings on the frequency of carriers of Neisseria meningitidis in a period of recrudescence of epidemic cerebrospinal meningitis].
Catania E; Ballarè GF
G Mal Infett Parassit; 1970 Feb; 22(2):170-4. PubMed ID: 4995703
[No Abstract] [Full Text] [Related]
[Next] [New Search]
